SS-31 Research Overview (also known as Elamipretide, Forzinity)
A water-soluble, cell-permeable tetrapeptide that selectively targets cardiolipin on the inner mitochondrial membrane, stabilizing electron transport chain supercomplexes and reducing reactive oxygen species generation. In September 2025, the FDA granted accelerated approval to SS-31 under the brand name Forzinity as the first drug ever approved to directly target mitochondrial function.
Researchers examining mitochondrial signaling may also wish to review Klotho, a longevity-associated protein studied in related aging and metabolic contexts.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
For a companion long-form discussion of the mitochondrial research context, see SS-31 and MOTS-C: The Mitochondrial Peptides Longevity Researchers Are Watching Closely.
What Is SS-31?
SS-31 (Elamipretide) is a synthetic tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds cardiolipin — a unique phospholipid found almost exclusively at the inner mitochondrial membrane that is essential for mitochondrial architecture, ATP synthase function, and the organization of electron transport chain supercomplexes.
Cardiolipin and Mitochondrial Protection
Cardiolipin is required for the structural integrity of electron transport chain supercomplexes, the stability of cytochrome c attachment to the inner membrane, and the function of ATP synthase. Oxidative stress causes cardiolipin peroxidation, which disrupts supercomplex organization, releases cytochrome c (triggering apoptosis), and profoundly impairs mitochondrial ATP production. SS-31 binds cardiolipin, protects it from peroxidation, and restores normal mitochondrial cristae architecture.
Cardiac and Renal Research
SS-31 has demonstrated dramatic cardioprotective effects in ischemia-reperfusion models — reducing infarct size by 40–50% and preserving ejection fraction. Human Phase 2 trials in heart failure with reduced ejection fraction showed significant improvements in cardiac energetics and 6-minute walk distance. SS-31 is also in Phase 3 trials for FSGS (focal segmental glomerulosclerosis) kidney disease, where mitochondrial dysfunction in podocytes is a key driver of pathology.
Quick Reference
| Literature-Reported Dose Range | 5–40 mg daily depending on application |
| Literature-Reported Frequency | Once daily, preferably morning |
| Literature-Reported Cycle Length | 4-12 weeks continuous use |
| Literature-Reported Washout | No mandatory break required - can be used continuously |
| Storage | Refrigerate after reconstitution, protect from light, use within 30 days |
| Sites Reported in Studies | Subcutaneous: Abdomen, thigh | IV: As directed by protocol |
| Timing | Morning for general use, pre-workout for performance, or as directed for clinical protocols |
Research Indications
Mitochondrial Health
Enhanced ATP Production
Improves mitochondrial efficiency and cellular energy generation
Oxidative Stress Reduction
Protects against reactive oxygen species at the source
Mitochondrial Disease Support
Shows promise for various mitochondrial disorders
Cardiovascular
Cardiac Protection
Reduces ischemia-reperfusion injury and improves heart function
Heart Failure Support
May improve cardiac energetics in heart failure patients
Exercise Tolerance
Enhances cardiac output and exercise capacity
Anti-Aging
Muscle Function
Reverses age-related decline in muscle mitochondria
Cognitive Protection
May protect against age-related cognitive decline
Cellular Rejuvenation
Restores youthful mitochondrial function
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General Mitochondrial Support | 5-10mg | Once daily | SubQ |
| Athletic Performance | 10-20mg | Once daily pre-workout | SubQ |
| Clinical Protocols | 40mg | Once daily | SubQ or IV |
| Acute Cardioprotection | 0.25mg/kg/hr | Continuous infusion | IV |
Timing
Morning for general use, pre-workout for performance, or as directed for clinical protocols. Typical onset: energy improvements within days, exercise capacity 2-4 weeks, clinical benefits 4-12 weeks.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Both support mitochondrial function through different mechanisms - SS-31 protects membranes while NAD+ enhances energy production
Both are mitochondrial peptides - MOTS-c regulates metabolism while SS-31 protects mitochondrial structure
Another mitochondrial-derived peptide - may work together to protect cellular function and reduce apoptosis
Different mechanisms - GHK-Cu works on gene expression while SS-31 directly protects mitochondria
No known interactions - BPC-157 focuses on tissue repair while SS-31 targets cellular energetics
Both have cardioprotective effects through different pathways - may be complementary
Reported Research Timeline
01Day 1–3 (reported in cited studies): subtle energy improvements, reduced fatigue
02Week 1–2 (reported in cited studies): better exercise endurance, faster recovery
03Week 2–4 (reported in cited studies): improved stamina, clearer thinking, better sleep quality
04Week 4–8 (reported in cited studies): significant improvements in exercise capacity
05Week 8–12 (reported in cited studies): sustained energy improvements, potential biomarker changes
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Excellent safety profile in clinical trials
No significant side effects reported at therapeutic doses
May cause mild injection site reactions
Monitor for allergic reactions (very rare)
Safe for long-term use based on current data
No known drug interactions
Seek Medical Attention If:
Severe injection site reactions
Signs of allergic reaction (rash, difficulty breathing)
Unusual fatigue or weakness (paradoxical reaction)
Any cardiovascular symptoms
Severe headaches or vision changes
Quality Indicators
Verified Marker
Pharmaceutical grade
SS-31 requires high purity due to clinical use - look for >98% purity
Verified Marker
Clear solution
Should dissolve completely into clear, colorless solution
Verified Marker
COA available
Certificate of analysis essential due to clinical applications
Acceptable Range
Light sensitive
Protect from light exposure - use amber vials if available
Acceptable Range
pH considerations
Solution pH should be near physiological (6.5-7.5)
Quality Concern
Discoloration
Any yellow or brown color indicates degradation
Research Citations
- Barth Syndrome Clinical Trial - FDA Approval (2025)
Human | 40mg daily | Phase 3 | FDA Approved - Phase 2 Trial for Primary Mitochondrial Myopathy (2018)
Human | 40mg daily | 12 weeks | 36 patients - Cardioprotection in Heart Failure Model (2019)
Human | 0.25mg/kg/hr infusion | During cardiac surgery - Age-Related Muscle Dysfunction Study (2020)
Animal model | Various doses | 8 weeks | Aged mice - Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction
Du X, Zeng Q, Luo Y, 2024, Mitochondrion - SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease
Zhu Y, Luo M, Bai X, 2022, Oxid Med Cell Longev - Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice
Russo S, De Rasmo D, Signorile A, 2022, Sci Rep - Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat experimental glaucoma model
Wu X, Pang Y, Zhang Z, 2019, Acta Biochim Biophys Sin (Shanghai) - SS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From Patients With DCMA, a Mitochondrial Cardiomyopathy
Machiraju P, Wang X, Sabouny R, 2019, Front Cardiovasc Med
Research Focus
Mitochondrial protection, Cardioprotection, Oxidative stress, Kidney disease, Anti-aging, Ischemia-reperfusion
Verified Vendors Carrying SS-31
Frequently Asked Questions
What should researchers watch for with SS-31?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with SS-31?
Day 1–3 (reported in cited studies): subtle energy improvements, reduced fatigue
How is SS-31 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →